Opexa Therapeutics Inc  

(Public, NASDAQ:OPXA)   Watch this stock  
Find more results for OPXA
+0.086 (9.76%)
Real-time:   2:33PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.88 - 0.99
52 week 0.73 - 2.56
Open 0.89
Vol / Avg. 209,601.00/285,809.00
Mkt cap 25.81M
P/E     -
Div/yield     -
EPS -0.83
Shares 27.75M
Beta 2.05
Inst. own 6%
Oct 16, 2014
Opexa Therapeutics Inc at Redchip Virtual Conference
Sep 9, 2014
Opexa Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Aug 14, 2014
Q2 2014 Opexa Therapeutics Inc Earnings Call
Aug 14, 2014
Q2 2014 Opexa Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -1353.07% -1315.03%
Operating margin -1354.46% -1140.20%
EBITD margin - -914.67%
Return on average assets -79.95% -109.63%
Return on average equity -108.06% -141.99%
Employees 38 -
CDP Score - -


2635 Technology Forest Blvd.
United States - Map
+1-281-7750600 (Phone)
+1-281-8728585 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company�s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).Tcelna is a personalized therapy that is specifically tailored to each patient�s disease profile. The TERMS study was a multi-center, randomized, double blind, placebo-controlled trial in 150 patients with RRMS or high risk Clinically Isolated Syndrome.

Officers and directors

Neil K. Warma President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Karthik Radhakrishnan CFA Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Donna R. Rill Chief Development Officer
Age: 60
Bio & Compensation  - Reuters
Timothy C. Barabe Director
Age: 61
Bio & Compensation  - Reuters
Hans-Peter Hartung M.D., Ph.D. Director
Age: 59
Bio & Compensation  - Reuters
Gail J. Maderis Independent Director
Age: 56
Bio & Compensation  - Reuters
Michael S. Richman Independent Director
Age: 52
Bio & Compensation  - Reuters
Scott B. Seaman CPA Independent Director
Age: 58
Bio & Compensation  - Reuters